Hansoh Pharmaceutical Group Company Limited 3692

This article first appeared on GuruFocus. Hansoh Pharmaceutical Group Co Ltd (HNSPF) recently announced a total dividend of $0.04 per share, with the ex-dividend date set for 2026-09-22. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 2.3% and

Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.

May 11 (Reuters) - Britain's GSK said on Monday it signed a deal with Hong Kong-listed Sino Biopharmaceutical to expand its presence in the growing mainland China market and sell its experimental

GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its Phase 3 trial in Chinese patients evaluating olatorepatide for the treatment of adults with obesity or who are overweight. Olatorepati

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is included in our list of the 11 Best Performing Stocks in the Last 12 Months. On January 16, 2026, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced that it has made a strategic amendment to its Exclusive Option and License Agreement with Hansoh (Shanghai) Healthtech Co., Ltd. Through this move, the company converted […]